Biomarker-driven personalization Matching the right drug to the right patient One of the most exciting developments is the use of biomarkers, measurable biological indicators, to predict how a patient will respond to therapy
More recently, the approval of the first oral GLP-1 analog, semaglutide (Rybelsus), for type 2 diabetes represents a major step forward in addressing one of the key challenges in this field: patient compliance associated with subcutaneous injections
A fundamental tenet of Dr
And from there I started learning. He ordered $1,200 worth of smart drugs from Europe, which pepped him up just as he had hoped they would
= 1), it was considered sufficient for inclusion
Patients should be monitored for signs of hyperventilation, fatigue, or altered consciousness